title: Rituximab chimeric anti-CD20 monoclonal antibody treatment for refractory hemolytic anemia in patients with lymphoproliferative disorders.
authors.forename: Giulio
authors.initials: G
authors.lastname: Trapè
authors.forename: Luana
authors.initials: L
authors.lastname: Fianchi
authors.forename: Marco
authors.initials: M
authors.lastname: Lai
authors.forename: Luca
authors.initials: L
authors.lastname: Laurenti
authors.forename: Roberta
authors.initials: R
authors.lastname: Piscitelli
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Leone
authors.forename: Livio
authors.initials: L
authors.lastname: Pagano
mesh_terms: D000328:Adult; D000368:Aged; D000744:Anemia, Hemolytic, Autoimmune / Q000188:drug therapy* / Q000209:etiology; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000633:toxicity; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008232:Lymphoproliferative Disorders / Q000150:complications*; D008297:Male; D008875:Middle Aged; D000069283:Rituximab; D016879:Salvage Therapy; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab